Skip to main content
In stock | Cellular Therapy

Afamitresgene Autoleucel

Oncology Type Solid Tumour (Sarcoma)
Drug Class / Mechanism Engineered TCR T-Cell Therapy, MAGE-A4 (HLA-A*02 restricted)
No Image
Description

Afamitresgene Autoleucel is classified as an Engineered TCR T-Cell Therapy, MAGE-A4 (HLA-A*02 restricted), sourced for use within our Cellular Therapy portfolio. Reach out to our team for full regulatory documentation, pricing, and current availability.

Therapeutic Category Cellular Therapy
Oncology Type Solid Tumour (Sarcoma)

Send Inquiry

Submit your details to get a formal quote for this product.

Step 1 of 3